A groundbreaking treatment at an Israeli hospital has demonstrated that targeted ultrasound waves can eliminate opioid cravings in as little as 20 minutes, offering hope for the millions struggling with prescription painkiller dependence. The patient, a man in his 40s who had been consuming 130 opioid pills daily, reported zero cravings within a week and has remained completely opioid-free since treatment, according to doctors at Rambam Health Care Campus in Haifa.

The opioid crisis remains one of the most pressing public health challenges globally. More than 1.25 million Americans have died from opioid-related overdoses since 1999, with nearly 80,000 deaths occurring in a single recent year, though abuse has apparently declined in recent years. In Israel, authorities estimate between 50 and 60 overdose and drug-related deaths annually, though medical experts suspect the actual figure is significantly higher.

How Does This New Ultrasound Technology Work?

The treatment uses a non-invasive neuromodulation approach developed by Insightec, an Israeli company headquartered in Haifa and Miami. The technology combines real-time magnetic resonance imaging (MRI) with high-intensity focused ultrasound to target specific brain regions without requiring surgical incisions or electrodes.

The key to the treatment's effectiveness lies in its precision. The multidisciplinary team at Rambam modulated electrical activity in the nucleus accumbens, a brain region responsible for the reward system and feelings of pleasure and satisfaction. By using energy from outside the body through magnetic fields, electrical currents, or ultrasound, doctors can alter brain activity to treat psychiatric and neurological conditions while encouraging neuroplasticity, the brain's ability to form new connections.

"This new technology makes it possible to intervene directly in the brain's electrical activity in a highly targeted way and to influence specific control centers depending on the condition being treated," explained Dr. Lior Lev Tov, director of the hospital's functional neurosurgery and the study's main investigator.

Dr. Lior Lev Tov, Director of Functional Neurosurgery at Rambam Health Care Campus

What Makes This Patient's Case Unique?

The patient treated at Rambam was the first to undergo this procedure while actively experiencing withdrawal symptoms, a distinction that provided researchers with valuable insights. He had suffered a neck injury years earlier and was prescribed opioids for pain management. Over time, his physical pain diminished, but he remained dependent on the medication simply to feel calm and maintain normal functioning.

"He couldn't even get out of bed without taking 30 pills," noted Dr. Amir Minerbi, head of the hospital's pain medicine institute who runs a specialized clinic for opioid withdrawal and addiction treatment. The patient's severe dependence made him an ideal candidate to test whether the technology could work under the most challenging circumstances.

Dr. Amir Minerbi

"During the treatment itself, a reduction of the patient's craving for opioids was already observed. A week later, tests came back negative for opioids and other substances, and the patient reported a craving score of zero out of 10," said Dr. Lev Tov.

Dr. Lior Lev Tov, Director of Functional Neurosurgery at Rambam Health Care Campus

The results extended beyond opioid addiction. The patient significantly reduced his cigarette smoking from three packs daily to just a few cigarettes and reported no desire to consume alcohol. This unexpected benefit suggests the technology may address multiple addictive behaviors simultaneously by targeting the shared neural pathways underlying all reward-driven dependencies.

What Conditions Could This Technology Treat Beyond Opioid Addiction?

Because addictions and cravings involving alcohol, nicotine, internet and social media use, gambling, and overeating all involve the brain's reward center, researchers believe the technology could eventually treat these conditions as well. The potential applications extend far beyond addiction:

• Psychiatric Conditions: Obsessive-compulsive disorder, post-traumatic stress disorder, eating disorders, and severe depression might be treated using this approach, according to Dr. Minerbi.
• Neurodegenerative Diseases: Attention-deficit hyperactivity disorder, Alzheimer's disease, and Parkinson's disease could potentially benefit from this non-invasive neuromodulation technology.
• Chronic Pain Syndrome: The technology may offer new treatment pathways for patients with persistent pain conditions that have not responded to conventional therapies.

"This new treatment directly targets the brain regions involved in addiction, and we hope that it will offer a safer and less traumatic solution for thousands of people dependent on opioids," stated Dr. Minerbi.

Dr. Amir Minerbi, Head of Pain Medicine Institute at Rambam Health Care Campus

Where Is This Treatment Available, and What Are the Limitations?

The Rambam trial remains in phase-1 research, meaning it has not yet been approved by the U.S. Food and Drug Administration. The first such treatment in the world was performed in 2022 by renowned neurosurgeon and neuroscientist Dr. Ali Rezai at West Virginia University, followed by 19 additional treatments since then. Subsequent treatments have been conducted at Cornell University in New York, Rambam in Israel, and the University of Florida.

Accessibility remains a significant challenge. Dr. Lev Tov noted that the treatment would be expensive because of the specialized medical equipment required and the need for a neurosurgeon to perform the procedure, meaning health fund clinics would not be able to offer it in the near term. At least a year of follow-up monitoring is necessary to confirm the long-term durability of the treatment's effects.

"From the day of treatment until the present, he has remained completely free of the opioid medication. His craving for opioids disappeared entirely, and he described feeling as though he had regained his life," reported Dr. Lev Tov.

Dr. Lior Lev Tov, Director of Functional Neurosurgery at Rambam Health Care Campus

Why Is This Breakthrough Important for Addiction Treatment?

Current addiction treatment typically addresses both physical withdrawal and psychological withdrawal, the latter of which can persist for months or years. Physical withdrawal involves tremors, excessive sweating, restlessness, dizziness, nausea, vomiting, constipation, and pain. Psychological withdrawal, driven by the brain's reward system, often proves more difficult to overcome than physical symptoms alone.

Dr. Minerbi emphasized that while opioid pain medications remain highly effective for short-term pain management and remain an important medical tool, a significant proportion of patients develop opioid addiction and continue seeking the medication regardless of its impact on their pain. Among long-term users, opioids become less effective for pain control while contributing to declining health, increased risk of premature death, reduced ability to function in daily life, and significantly decreased quality of life.

The significance of this work extends far beyond addiction treatment alone. By demonstrating a non-invasive way to access and modulate deep brain regions involved in reward and motivation, researchers have opened a new frontier in neuroscience and psychiatric medicine. As Dr. Lev Tov described it, this represents "nothing short of a medical and therapeutic breakthrough". While much work remains before this technology becomes widely available, the successful treatment of this patient offers compelling evidence that targeted ultrasound may provide a safer, less traumatic alternative to conventional addiction treatment for thousands of people struggling with opioid dependence.

Dr. Lev Tov